A5068737731- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Endometrial and Cervical Cancer Treatments
- Renal cell carcinoma treatment
- Intraperitoneal and Appendiceal Malignancies
- Bladder and Urothelial Cancer Treatments
- Cancer Treatment and Pharmacology
- Cancer survivorship and care
- Monoclonal and Polyclonal Antibodies Research
- Breast Cancer Treatment Studies
- Chemotherapy-induced cardiotoxicity and mitigation
- Medical Imaging and Pathology Studies
- Renal Diseases and Glomerulopathies
- Immunotherapy and Immune Responses
- Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Cancer Mechanisms and Therapy
- Estrogen and related hormone effects
- Childhood Cancer Survivors' Quality of Life
- Uterine Myomas and Treatments
- Cancer Risks and Factors
- Craniofacial Disorders and Treatments
- BRCA gene mutations in cancer
- Fetal and Pediatric Neurological Disorders
Institut Jean Godinot
2014-2024
Centre Antoine Lacassagne
2021
The proinflammatory cytokine Interleukin 17A (hereafter named IL–17A) or IL-17A producing cells are elevated in breast tumors environment and correlate with poor prognosis. Increased is associated ER(−) triple negative reduced Disease Free Survival. However, the pathophysiological role of cancer remains unclear although several studies suggested its involvement cell dissemination. Here we demonstrated that a subset infiltrated IL-17A-producing cells. seems mainly to negative/basal-like...
Single-agent carboplatin is often proposed instead of a conventional carboplatin-paclitaxel doublet in vulnerable older patients with ovarian cancer. Such an approach could have detrimental effect on outcomes for these patients.To compare the feasibility, efficacy, and safety single-agent every 3 weeks, weekly carboplatin-paclitaxel, or every-3-weeks cancer.This international, open-label, 3-arm randomized clinical trial screened 447 women 70 years newly diagnosed stage III/IV cancer by...
Abstract This open-label, non-comparative, 2:1 randomized, phase II trial (NCT03275506) in women with stage IIIC/IV high-grade serous carcinoma (HGSC) for whom upfront complete resection was unachievable assessed whether adding pembrolizumab (200 mg every 3 weeks) to standard-of-care carboplatin plus paclitaxel yielded a rate (CRR) of at least 50%. Postoperatively patients continued assigned treatment maximum 2 years. Postoperative bevacizumab optional. The primary endpoint independently CRR...
Abstract PD-1/PD-L1 blockade has so far shown limited survival benefit for high-grade ovarian carcinomas. By using paired samples from the NeoPembrOv randomized phase II trial (NCT03275506), which primary outcomes are published, and by combining RNA-seq multiplexed immunofluorescence staining, we explore impact of NeoAdjuvant ChemoTherapy (NACT) ± Pembrolizumab (P) on tumor environment, identify parameters that correlated with response to immunotherapy as a pre-planned exploratory analysis....
5501 Background: We report the results of a window-of-opportunity phase 2 trial using neoadjuvant nivolumab + ipilimumab followed by standard chemoradiation therapy (RTCT) in cervical squamous cell carcinoma pts CD8 /FOXP3 ratio as surrogate marker immune checkpoint blockade (ICB) situ effect. Association with better clinical outcome after chemotherapy and higher was described cancer pts. However, modulation ICB correlation treatment response needs to be characterized. Methods: The primary...
Aims . The differences between the 2007 and 2013 ASCO/CAP HER2 guidelines have been compared. We also discussed potential consequences in our pathological practice. Material Methodology 189 fluorescence situ hybridisation (FISH) tests were performed from 1016 preliminary immunohistochemical (IHC). All cases reviewed reclassed following recommendations. Results version decreased false-negative IHC (3/118 versus 1/54,<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"...
In ERBB2 (formerly HER2)-positive metastatic breast cancer (MBC), combining trastuzumab and pertuzumab with taxane-based chemotherapy is the first line of standard care. Given that plus was proven effective in ERBB2-positive MBC, even without chemotherapy, whether optimal first-line strategy could be alone instead unresolved.
Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB–IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study assessed treatment administration and outcomes in the French real-world setting. Patients Methods: Eligible patients were aged ≥ 18 years with planned bevacizumab-containing newly diagnosed cancer. primary objective was to assess safety profile...
PurposeCombining bevacizumab with paclitaxel significantly improves progression-free survival (PFS) versus alone in HER2-negative metastatic breast cancer (MBC). Eribulin is active and tolerable pretreated MBC. To assess whether eribulin may offer a more yet effective combination partner for bevacizumab, we evaluated bevacizumab/eribulin regimen as first-line therapy MBC.MethodsIn this single-arm phase II study, patients histologically confirmed MBC no prior chemotherapy received 1.23 mg/m2...
Abstract Background Germ cell tumors and sex cord stromal are rare cancers of the ovary. They mainly affect young women associated with a high survival rate. The standard treatment involves conservative surgery combined chemotherapy [bleomycin, etoposide cisplatin (BEP)] depending on stage prognostic factors, as for testicular cancers. As reported in cancer survivors, may induce sequelae impacting quality life, which has not yet been evaluated survivors germ tumors. GINECO-VIVROVAIRE-Rare...
9122 Background: Few trials have prospectively evaluated MBC chemotherapy tolerance and outcomes in the elderly. Due to its decreased cardiotoxicity, PLD appears be an interesting option. Methods: This trial was designed evaluate tumour response (primary endpoint), feasibility after 6 courses of adapted dose (40mg/m²/4 wks) first line hormone-resistant MBC. Results: Out 60 patients (median age 77, range 70-88), 15% had performance status≥2, 13% initially HR-negative tumours 70% visceral...
Abstract Author Summary Background. Neoadjuvant treatment provides a unique opportunity to evaluate individual tumor sensitivity. This study evaluated whether response-guided strategy could improve clinical outcome compared with standard treatment. Methods. Overall, 264 previously untreated stage II–III operable breast cancer patients were randomized receive either (arm A, n = 131), consisting of fluorouracil, epirubicin, and cyclophosphamide (FEC100: 500, 100, 500 mg/m2, respectively, for 3...
Abstract The everolimus–exemestane combination is indicated in advanced breast cancer treatment and usually well tolerated. objective of the study was to determine frequency everolimus lung side effects investigate their imaging characteristics on positron emission tomography with 18F-fluoro-deoxy-glucose combined computerized ( 18 F-FDG PET/CT). Our single-center retrospective descriptive systematically included all patients metastatic treated by this (n = 29 representing 57 Number segments...
To evaluate the efficacy and safety of regorafenib versus tamoxifen in platinum-sensitive ovarian cancer biological recurrence, defined by CA-125 increase without radiological (RECIST criteria) or symptomatic evidence progression.116 patients with presenting an isolated were planned to be randomized. Regorafenib was administered orally at 160 120 mg daily, 3 weeks on/1 week off 40 until disease progression development unacceptable toxicity. The primary endpoint Progression-Free Survival,...
<h3>Introduction/Background</h3> Clinical benefit to immunotherapy (ICPI) has been limited date in high-grade serous ovarian carcinoma (HGSOC), underpinning the necessity of better patient's selection. Conversely, peripheral blood parameters such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR) and lymphocyte-to-monocyte (LMR) have correlated ICPI various malignancies. As such, present ancillary study from NEOPEMBROV/GINECO phase II trial (NCT03275506) assessed these...
5569 Background: Ineov was a phase Ib randomized trial of neoadjuvant carboplatin/paclitaxel (NACT) + durvalumab (D) +/- tremelimumab (T) in unresectable OC. We previously reported safety and encouraging complete resection rates (CC0=70%) pathological response (pCR=18%) at interval debulking surgery (IDS). However there were no significant differences with the addition T to D+NACT. Here we report survival outcomes immune correlates focus on long-term responders. Methods: Pts stage IIIC/IV OC...
Abstract Background: In patients (pts) with early breast cancer (BC), the level of expression estrogen receptor (ER) evaluated by immunohistochemistry is prognostic and predictive while progesterone (PR) has an additional value. Allred scoring combines percentage positive cells intensity staining. It widely used for treatment choice BC. metastatic setting, its role less defined. Methods: The ESME database a French National cohort all consecutive pts who initiated first-line BC (MBC) between...
Objective Treatment of high-grade serous ovarian carcinomas relies on surgery and chemotherapy, potentially followed by bevacizumab and/or poly (ADP-ribose) polymerase inhibitors (PARPi). The modeled CA-125 ELIMination rate constant K (KELIM) is a pragmatic indicator tumor primary chemosensitivity. Although it well established that BRCA mutations are associated with platinum sensitivity, the relationship between status KELIM score has yet to be elucidated. This study aimed evaluate...